Nova Mentis Life Science Corp. has received an exemption under Section 56 of the Health Canada Controlled Drugs and Substances Act to advance a phase 2a clinical trial examining oral microdose psilocybin therapy for fragile X syndrome.
According to a company release, the exemption allows approved medical professionals to legally prescribe certain controlled substances to improve care for treatment-resistant conditions.
“Securing this latest regulatory approval from the Canadian government is a critical step in Nova’s research and drug development program and allows us to begin our